教师基本信息：
姓名：王鹏飞
职称：正高
职务：青年研究员、党委副书记
电子邮箱：pengfei_wang@fudan.edu.cn
办公地点：复旦大学生命科学学院E501-4
个人网页/课题组主页：https://scholar.google.com/citations?user=fWjlGn8AAAAJ&hl=en
研究方向：
抗病毒药物和疫苗
个人简介：
王鹏飞，2006-2010年就读于北京师范大学获得学士学位；2010-2015年就读于复旦大学生命科学学院并获得博士学位； 2015-2019年于美国洛克菲勒大学从事博士后研究；2020-2021年任美国哥伦比亚大学助理研究员，2021年7月起任复旦大学生命科学学院青年研究员、博士生导师。长期从事新发传染病防治方面的研究，包括病毒感染、变异和免疫保护机制；抗病毒中和抗体及药物新靶点；疫苗开发等。至今发表论文80多篇；累计引用10000余次；其中以（共同）第一或通讯作者身份在Nature (3篇)、Nature Reviews Immunology、Cell Host & Microbe (3篇)、Cell Discovery (3篇)、Nature Communications (3篇)等期刊发表论文40多篇。
授课情况：
感染与免疫（H）
招生专业：
遗传学、微生物学、免疫学
科研项目：
科技部重点研发、国自然面上项目等
获奖情况：
科睿唯安（Clarivate）“全球高被引科学家”（2023-2024）、爱思维尔（Elsevier）“全球前2%顶尖科学家榜单”（2023-2025）
代表性论文和论著：
第一（#）/通讯（*）作者论文
2025年
1. Shi J#, Zhao X#*, Jin X#, Li J#, Liu Y#, Liu H#, Hu Y-F#, Chen Z, Xiao Y, Wang L, Wang Y, He Y, Chai Y, Hu B, Shuai H, Wang Y, Li X, Jiang S, Zhang Y, Zhang X, Chan W-M, Chen L-L, Cai J-P, Sui B, Zhang H, Yang D, Zhu L, Yuan S, Zhou J, Huang J-D, Yuen K-Y, To KK-W, Chan JF-W, Zhang B-Z, Wang Q, He M*, Sun L*, Wang P*, Chu H*. Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1. Nature Communications. 2025;16(1):11002.
2. Xie M#, Qiu Y#, Zhao X#, Shi J#, Liu Y#, Zhang Q#, He J#, Li J#, Liu L, Sun S, Zhu Y, Mao Q, Long Y, Oliveira TY, Wang Z, Zhou Y, Yan Y, Xia A, Zai W, Mayer CT, Xie Y, Jiang S, Lu L, Xia R*, Wu F*, Sun L*, Wang P*, Chu H*, Wang Q*. Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution. Nature Communications. 2025;16(1):10566.
3. Zhang M#, Gao Z#, Feng S, Wang X, Wang H, Yang C, Lin X, Xu Z, Zhang N, Li Y, Tian H, Jin N, Yu B*, Wang P*, Li C*, Yu X*. A Synthetic Liposome Nanoparticle Vaccine Platform for Broad-Spectrum Vaccine Design. Nano Letters. 2025, 25, 41, 14832–14842.
4. Yu L#, Wang Y#, Liu Y#, Xing X#, Li C#, Wang X, Shi J, Ma W, Li J, Chen Y, Qiao R, Zhao X, Tian S, Gao M, Wen S, Xue Y, Qiu T, Yu H, Guan Y*, Chu H*, Sun L*, Wang P*. Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection. Communications Biology. 2025; 8 (1), 378.
5. Liu J#, Wang X#, Zhang Y#, Liu C#, Zhang M, Li C, Liu P, Li S, Wei K, Cai Y, Yu H, Hu Z*, Wang P*, Zhang Y*. Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development. Infectious Diseases of Poverty. 2025;14(1):12. doi: 10.1186/s40249-025-01280-1.
6. Qiao R#, Liu Y#, Mao Q, Li J, Lu Y, Shi J, Li C, Yu J, Gong J, Wang X, Shao Y, Sun L, Zhang W, Yu H, Chu H*, Wang P*, Zhao X*. Novel Trispecific Neutralizing Antibodies with Enhanced Potency and Breadth Against Pan‐Sarbecoviruses. MedComm. 2025; 6(5): e70191.
7. Qiao R#, Li J#, Gong J, Shao Y, Yu J, Chen Y, Lu Y, Yang L, Lin L, Hu Z, Wang P*, Zhao X*, Zhang W. Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection. Vaccines. 2025;13(6):635.
2024年
8. Wang X#, Jiang S#, Ma W#, Zhang Y*, Wang P*. Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies. Signal Transduction and Targeted Therapy. 2024;9(1):123.
9. Zhao X#, Qiu T#, Huang X#, Mao Q#, Wang Y#, Qiao R#, Li J, Mao T, Wang Y, Cun Y, Wang C, Luo C, Yoon C, Wang X, Li C, Cui Y, Zhao C, Li M, Chen Y, Cai G, Geng W, Hu Z, Cao J, Zhang W, Cao Z*, Chu H*, Sun L*, Wang P*. Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination. Cell Discovery. 2024;10(1):14.
10. Wang X#, Jiang S#, Ma W#, Li X, Wei K, Xie F, Zhao C, Zhao X, Wang S, Li C, Qiao R, Cui Y, Chen Y, Li J, Cai G, Liu C, Yu J, Li J, Hu Z, Zhang W, Jiang S, Li M*, Zhang Y*, Wang P*. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster. Cell Host & Microbe, 2024;32:25-34.e5.
11. Zhou H#*, Leng P#, Wang Y, Yang K, Li C, Ojcius DM, Wang P*, Jiang S*. Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants. Science Bulletin. 2024; 69(15): 2456-2470.
12. Liu Y#, Zhao X#, Shi J#, Wang Y#, Liu H#, Hu YF#, Hu B, Shuai H, Yuen TT, Chai Y, Liu F, Gong HR, Li J, Wang X, Jiang S, Zhang X, Zhang Y, Li X, Wang L, Hartnoll M, Zhu T, Hou Y, Huang X, Yoon C, Wang Y, He Y, Zhou M, Du L, Zhang X, Chan WM, Chen LL, Cai JP, Yuan S, Zhou J, Huang JD, Yuen KY, To KK, Chan JF*, Zhang BZ*, Sun L*, Wang P*, Chu H*. Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3. Nature Communications. 2024;15(1):8728.
13. Zhao X#*, Qiao R#, Hao M#, Xu L#, Wang D, Lu Y, Li J, Wu J, Li Y, Cheng T, Zhang W, Zhao J*, Wang P*. Vascular endothelial growth factor receptor 2 as a potential host target for the inhibition of enterovirus replication. Journal of Virology. 2024: e0112924.
14. Zhao C#, Cai G#, Jiang S#, Wang X, Li C, Liu X, Qiao R, Zhao X, Cui Y, Chen Y, Li J, Liu C, Yu J, Gong J, Wang P*. Broad-spectrum coronavirus neutralization induced by hetero RBD-Fc protein vaccine. Journal of Medical Virology. 2024; 96(9): e29917.
15. Li M#, Zhao C#, Shi J#, Wang X#, Liu Y, Zhao X, Cai G, Chu H*, Wang P*. Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes. Emerging Microbes & Infections. 2024; 13(1): 2404166.
16. Yang L#, Kim TW#, Han Y#, Nair MS#, Harschnitz O#, Zhu J#, Wang P#, Koo SY, Lacko LA, Chandar V, Bram Y, Zhang T, Zhang W, He F, Pan C, Wu J, Huang Y, Evans T, van der Valk P, Titulaer MJ, Spoor JKH, Furler O'Brien RL, Bugiani M, D J Van de Berg W, Schwartz RE*, Ho DD*, Studer L*, Chen S*. SARS-CoV-2 infection causes dopaminergic neuron senescence. Cell Stem Cell. 2024, 31(2): 196-211.e6.
17. Wang X#, Zhang M#, Wei K, Li C, Yang J, Jiang S, Zhao C, Zhao X, Qiao R, Cui Y, Chen Y, Li J, Cai G, Liu C, Yu J, Zhang W, Xie F*, Wang P*, Zhang Y*. Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection. Vaccines. 2024;12(5):464.
2023年
18. Zhao C, Cai G, Zhang X, Liu X, Wang P*, Zheng A*. Comparative Analysis of Bisexual and Parthenogenetic Populations in Haemaphysalis Longicornis. Microorganisms. 2024;12(4):823.
19. Wang X#, Jiang S#, Jiang S#, Li X#, Ai J#, Lin K#, Lv S#, Zhang S#, Li M#, Li J*, Dai L*, Hu Z*, Zhang W*, Zhang Y*, Wang P*. Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by Breakthrough Infection Sera from Previous and Recent Waves in China. Cell Discovery, 2023, 9(1):64.
20. Wang X#, He X#, Jiang S#, Fu Z#, Jiang S, Zhao X, Zhao C, Li Y, Li D, Zhang W, Ai J*, Zhang Y*, Xu C*, Wang P*. Limited enhancement of antibody and B-cell responses to prototype booster vaccination following SARS-CoV-2 Delta breakthrough infection. Journal of Medical Virology. 2023; 95(2): e28540.
21. Chen Y#, Zhao X#, Zhou H#, Zhu H, Jiang S*, Wang P*. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nature Reviews Immunology. 2023, 23, 189–199.
22. Wang H#, Xue Q#, Zhang H#, Yuan G#, Wang X#, Sheng K#, Li C#, Cai J, Sun Y, Zhao J, Lu J, Fang S, Yang Y, Zhang Y, Huang Y, Wang J, Xu JH, Jiang MX, Wang X, Shen L, Liu Y, Liu Q, Zhang Q, Wang S, Wang P*, Qiu C*, Ai J*, Zhang W. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination. Emerging Microbes & Infections. 2023,5:2249121.
23. Qiao R#, Tang W#, Li J#, Li C, Zhao C, Wang X, Li M, Cui Y, Chen Y, Cai G, Wu Q, Zhao X*, Wang P*. Structure-based virtual screening of ROCK1 inhibitors for the discovery of Enterovirus-A71 antivirals. Virology. 2023, 585:205-14.
24. Wang X#, Li M#, Lu P#, Li C, Zhao C, Zhao X, Qiao R, Cui Y, Chen Y, Li J, Cai G, Wang P*. In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG. Pathogens. 2023, 30;12(9):1108.
2022年
25. Ai J#, Wang X#, He X#, Zhao X#, Zhang Y#, Jiang Y#, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z*, Zhang W*, Wang P*. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 sub-lineages. Cell Host & Microbe, 2022, 10;30(8):1077-1083.e4.
26. Wang X#, Ai J#, Li X#, Zhao X#, Wu J#, Zhang H#, He X#, Zhao C, Qiao R, Li M, Cui Y, Hu Z*, Xu C*, Zhang W*, Wang P*. Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera. Cell Discovery, 2022, 8(1):110.
27. Wang X#, Zhao X#, Song J#, Wu J#, Zhu Y#, Li M, Cui Y, Chen Y, Yang L, Liu J, Zhu H, Jiang S, Wang P*. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes & Infections. 2022;11(1):477-481.
28. Zhao X, Li C, Chiu MC, Qiao R, Jiang S, Wang P*, Zhou J*. Rock1 is a novel host dependency factor of human enterovirus A71: implication as a drug target. Journal of Medical Virology. 2022, 94(11):5415-5424.
29. Wang X#, Zhao X#, Cui Y#, Qiao R#, Li M#, Chen Y, Yang L, Jiang S, Wang P*. Neutralization of distinct Omicron sublineages by longitudinal vaccination sera. Journal of Medical Virology 2022, 94(11):5090-5092.
30. Wang P#, Casner RG#, Nair MS#, Yu J, Guo Y, Wang M, Chan JF, Cerutti G, Iketani S, Liu L, Sheng Z, Chen Z, Yuen KY, Kwong PD, Huang Y, Shapiro L*, Ho DD*. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerging Microbes & Infections. 2022, 11(1):147-157.
2021年及之前
31. Wang P#, Nair MS#, Liu L#, Iketani S#, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y*, Ho DD*. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature. 2021, 593, 130–135.
32. Wang P#*, Casner RG#, Nair MS#, Wang M, Yu J, Cerutti G, Liu L, Kwong PD, Huang Y, Shapiro L*, Ho DD*. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. Cell Host & Microbe, 2021, 29 (5), 747-751. e4.
33. Liu L#, Wang P#, Nair MS#, Yu J#, Rapp MA#, Wang Q#, Luo Y, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y*, Shapiro L*, Ho DD*. Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike. Nature, 2020, 584, 450–456.
34. Han Y#, Duan X#, Yang L#, Nilsson-Payant BE#, Wang P#, Duan F#, Tang X#, Yaron TM#, Zhang T, Uhl S, Bram Y, Richardson C, Zhu J, Zhao Z, Redmond D, Houghton S, Nguyen D, Xu D, Wang X, Jessurun J, Borczuk A, Huang Y, Johnson JL, Liu Y, Xiang J, Wang H*, Cantley LC*, tenOever BR*, Ho DD*, Pan FC*, Evans T*, Chen HJ*, Schwartz RE*, Chen S*. Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids. Nature. 2021, 589, 270–275.
35. Wang P, Gajjar MR, Yu J, Padte NN, Gettie A, Blanchard JL, Russell-Lodrigue K, Liao LE, Perelson AS, Huang Y, Ho DD. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. PNAS. 2020, 117(30):18002-18009.
36. Wang P#, Liu L#, Nair MS#, Yin MT#, Luo Y, Wang Q, Yuan T, Mori K, Solis AG, Yamashita M, Lawrence J. Purpura LJ, Laracy JC, Yu J, Sodroski JG, Huang Y, Ho DD. SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease. Emerging Microbes & Infections. 2020, 9(1):2091-2093.
37. Wang P. Anti-HIV Passive Immunization in Animal Models. Journal of HIV & Retro Virus. 2018, 4 (1): 4.
38. Wang P, Lu P, Qu X, Shen Y, Zeng H, Zhu X, Zhu Y, Li X, Wu H, Xu J, Lu H, Ma Z*, Zhu H*. Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui. Scientific Reports. 2017, 25;7(1):9451.
39. Wang P, Qu X, Zhou X, Shen Y, Ji H, Fu Z, Deng J, Lu P, Yu W, Lu H, Zhu H. Two cellular microRNAs, miR-196b and miR-1290, contribute to HIV-1 latency. Virology. 2015, 486:228-38.
40. Wang P, Qu X, Wang X, Zhu X, Zeng H, Chen H, Zhu H. Specific reactivation of latent HIV-1 with designer zinc-finger transcription factors targeting the HIV-1 5′-LTR promoter. Gene Therapy. 2014, 21(5):490-495.
41. Wang P, Qu X, Wang X, Liu L, Zhu X, Zeng H, Zhu H. As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB. Antiviral Research. 2013, 100 (3): 688-697.
42. Qu X#, Wang P#, Ding D, Li L, Wang H, Ma L, Zhou X, Liu S, Lin S, Wang X, Zhang G, Liu S, Liu L, Wang J, Zhang F, Lu D, Zhu H. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Research. 2013, 41 (16): 7771-7782.
43. Jiao Y#, Wang P#, Zhang H, Zhang T, Zhang Y, Zhu H*, Wu H*. HIV-1 Co-Receptor Usage Based on V3 Loop Sequence Analysis: Preferential Suppression of CXCR4 Virus Post HAART? Immunological Investigations 2011, 40(6):597-613.